HPV L1 Gene Codon Optimization for High-Yield VLP Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines do not effectively prevent infections from HPV 58, a genotype commonly associated with cervical cancer in China and East Asian countries, due to low expression levels of the L1 protein in vitro, which limits vaccine production and availability.
Innovation Solution
Optimally modified HPV 16, 58, 18, 6, and 11 L1 gene sequences are used to enhance protein expression in insect cells, producing high yields of virus-like particles (VLPs) that induce specific immune responses, and a multivalent vaccine is developed to target these genotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild type HPV L1 genes are used for expression, then the vaccine can be produced, but the protein expression level is low and vaccine yield is limited
Solution Approach 1:
The patent applies parameter changes by modifying the HPV L1 gene sequences through codon optimization, removing harmful elements (transcription stop codons, splicing sites, polyadenylation signals), and adjusting gene structure to enhance protein expression. These modifications transform the wild type gene into an optimally modified version that produces significantly higher L1 protein levels and vaccine yield in insect cell culture systems.
2Reliability
If current HPV vaccines are used, then protection against some genotypes is achieved, but they do not effectively prevent HPV 58 infection
Solution Approach 1:
The patent implements universality by developing a multivalent vaccine that incorporates optimally modified L1 genes from multiple HPV genotypes (16, 58, 18, 6, and 11) into a single vaccine formulation. This enables the vaccine to provide protective immunity against all included genotypes simultaneously, with particular emphasis on covering HPV 58, which is prevalent in China and East Asia, thereby enhancing both effectiveness and adaptability.
3Reliability
If HPV 58 is included in the vaccine, then protection against this genotype is provided, but the expression level of HPV 58 L1 protein was originally low
Solution Approach 1:
The patent applies parameter changes specifically to the HPV 58 L1 gene by removing transcription stop codons, optimizing codon usage for insect cells, eliminating splicing sites and polyadenylation signals, and simplifying mRNA secondary structures. These modifications dramatically increase the expression level of HPV 58 L1 protein, enabling effective vaccine production while maintaining protection against this critical genotype.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified HPV L1 genes significantly increase protein expression and vaccine yield, enabling the production of effective multivalent vaccines that induce synchronized immune responses, effectively preventing HPV infections associated with HPV 16, 58, 18, 6, and 11.
Implementation Method 1
L1 protein may be self-assembled into virus-like particles (VLPs) when expressed in vitro
Implementation Method 2
Such antibodies are highly genotype-specific and usually have no cross-neutralizing activities. Thus, vaccination with one HPV VLP genotype is not able to prevent the infection of other HPV genotypes
Data Source
AI summary
Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.